Results of pneumococcal vaccines studied at the surfaces of many products worldwide
About a third of available pneumococcal vaccines administered in developed countries are treated with ingredients such as phosphate bromine iodine and a nucleotide. The vaccines are therefore bacteriological immunogenic hormonal and pharmacological and have to be stored and maintained for two-to-four months after use. By contrast many commercially available vaccines for Streptococcus pneumoniae can be administered subcutaneously.
Researchers at the Institute of Clinical Food ResearchIEI a Copenhagen-based collaborative research centre that leads a large European project on antimicrobial and environmental reasons why people are allergic to food was invited to present results from a study of the efficacy of subcutaneous inoculations of subcutaneous lactic acid (SLCO) a probiotic community vaccine at the European Food Safety Authority Symposium in Copenhagen on 24 March. SLCO subcutaneous inoculations have become widely used worldwide in European countries such as the United States and Denmark.
The study investigated SLCO subcutaneous inoculation efficacy and side-effects in three European countries from the beginning of the SLCO vaccine field trials. The majority of the study participants were from the United States Poland and Romania. The study was performed in cooperation with Institut Pasteur and the Royal Institute of Copenhagen and the Department of Clinical Microbiology and Immunology of the University of Copenhagen.
All the vaccine participants had a non-alcoholic bacterial gastroenteritis (NIBG) diagnosis; 2 of them had a clinical diagnosis of upper gastrointestinal infection dry mouth associated with repeated stomach surgery or post-surgery bacterial bronchiolitis. Two patients did not complete the study because no vaccine was administered subcutaneously. Two other patients were provided with SLCO fluids via a mesh bag.
Subcutaneous inoculations are a safe alternative to animal testing. It was interesting that SLCO vaccination induced an antibody response in nIBG patients. We are hoping the results of this study will be able to inform their decisions. It is important to continue research to improve SLCO vaccination use says Dr. Kristin Nordstrand Srensen Olsen clinical director of immunology gastroenterology and infectious disease at Institut Pasteur.